ESC preview – Medicines Company hopes for a starring role
Novartis has been reduced to a Paragon data dredge, but results with The Medicines Company’s inclisiran, Astrazeneca’s Brilinta and Cellaegis’ AutoRIC device should pique…
Medicines Company goes on the hunt for heartening Orion data
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
Alnylam touts givosiran win despite toxicity fears
Alnylam looks likely to get approval for its second RNAi candidate, givosiran. But toxicity issues have tainted the Envision trial win.
JP Morgan 2019 – Alnylam turns Onpattro frown upside-down
Alnylam appears to have turned its Onpattro launch around, but is adamant that investors should have been more patient all along.
M&A: 2017 proves snooze-worthy on the acquisition front
Pharma and biotech takeover activity slumps to a five-year low in 2017.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.